Free Trial

TerrAscend (OTCMKTS:TSNDF) Stock Price Down 0.5% - Time to Sell?

TerrAscend logo with Medical background

Key Points

  • TerrAscend Corp. shares fell 0.5% to $0.79, with a trading volume decrease of 14% compared to the average.
  • In Q2, the company reported a loss of ($0.03) earnings per share, missing analyst estimates by ($0.01), despite revenue of $65.01 million.
  • The stock's market capitalization stands at $240.70 million, with a negative net margin of 40.86% and a debt-to-equity ratio of 1.94.
  • MarketBeat previews the top five stocks to own by October 1st.

Shares of TerrAscend Corp. (OTCMKTS:TSNDF - Get Free Report) dropped 0.5% on Tuesday . The company traded as low as $0.78 and last traded at $0.79. Approximately 490,076 shares changed hands during trading, a decline of 14% from the average daily volume of 573,030 shares. The stock had previously closed at $0.79.

TerrAscend Price Performance

The stock has a fifty day moving average of $0.73 and a two-hundred day moving average of $0.48. The stock has a market capitalization of $240.70 million, a price-to-earnings ratio of -1.92 and a beta of 1.56. The company has a current ratio of 1.45, a quick ratio of 1.07 and a debt-to-equity ratio of 1.94.

TerrAscend (OTCMKTS:TSNDF - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.01). TerrAscend had a negative net margin of 40.86% and a negative return on equity of 23.19%. The business had revenue of $65.01 million for the quarter, compared to analyst estimates of $64.87 million. As a group, equities research analysts forecast that TerrAscend Corp. will post -0.14 earnings per share for the current year.

TerrAscend Company Profile

(Get Free Report)

TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. The company produces and distributes hemp-derived wellness products to retail locations; and manufactures vaporizables, concentrates, topicals, tinctures and edibles. It also operates retail dispensaries under the Apothecarium and State Flower brand names.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in TerrAscend Right Now?

Before you consider TerrAscend, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TerrAscend wasn't on the list.

While TerrAscend currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.